A narrative review of survival normalization in non-Hodgkin lymphoma: useful for better patient counselling and an endpoint for clinical trials?

Abstract

As numerous new therapies against non-Hodgkin lymphoma (NHL) are under investigation, there is an increasing interest in surrogate endpoints (SEPs) that can reduce the costs and duration of clinical trials and thereby accelerate delivery of new treatments to patients with unmet medical needs. The time to normalization of overall survival (OS) is an endpoint that is increasingly explored for this purpose. The patient survival is considered normalized when it matches the corresponding survival of a matched background population. The time point where this occurs is also useful for patient counselling and for